NDAORALTABLET
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
4/8 — Partial
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEYSARA (sarecycline HCl) is an oral tetracycline-class antibiotic approved in 2018 for the treatment of moderate-to-severe acne vulgaris. It is a narrow-spectrum tetracycline designed to target pathogenic bacteria while preserving beneficial microbiota. The drug represents a newer generation antibiotic option within a mature therapeutic category.
$0.658MPart D
Peak6.3 years to LOEProduct is at peak lifecycle stage with modest Part D claims, indicating stable but niche market penetration in oral acne therapy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Started Apr 2026
30 enrolled
Acne Vulgaris
Sarecycline Truncal Acne Safety and Efficacy Response
Started Mar 2021
10 enrolled
Acne Vulgaris
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
Started Mar 2021
300 enrolled
Acne Vulgaris
Career Relevance
Working on SEYSARA offers exposure to mature-market brand management, competitive positioning against generics, and dermatology specialty channels. Career trajectory is best suited for professionals seeking stability in a niche segment rather than high-growth expansion roles.
Worked on SEYSARA at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.